News

LARTRUVO's indication is approved under Accelerated Approval, and is based on data from the Phase 2 portion of the pivotal JGDG trial. Continued approval for this indication may

LIMT HDV is a 30-patient study designed to evaluate the safety, tolerability and efficacy of two dose levels of Lambda after 48 weeks of treatment.  LIMT HDV is

SOBI003 will be included in the EU Community Register of Orphan Medicinal Products. MPS IIIA or Sanfilippo A syndrome is an inherited systemic lysosomal storage disease with a

It is the second collaboration between both the parties focusing on dengue. The first one was related to the development of a botanical drug to treat dengue. The

Life sciences-focused venture capital firm Medicxi Ventures has agreed to invest up to €9m in Mavalon. Mavalon is developing an orally available small molecule able to induce Glial

ONIVYDE is the first and only approved treatment option for this patient population. With this approval, Shire is authorized to market ONIVYDE in the 28 Member States of

Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government. AML is the most lethal of the

The establishment of Clinigen KK further expands the Group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015. Alongside the launch, Clinigen KK will transfer the

Follitropin delta is the first recombinant follicle stimulating hormone (FSH) derived from a human cell line. It has been developed for individualized dosing depending on a woman’s serum